I hate watching experimental therapeutics sessions where they say their drug is active in a wide range of “solid tumors” yet breast was excluded. We need new drugs too! Especially

Rebecca Shatsky, MD· @Dr_RShatsky · X·2026-10-24 21:03· 20 小时前评分45

正文 · 原文

I hate watching experimental therapeutics sessions where they say their drug is active in a wide range of “solid tumors” yet breast was excluded. We need new drugs too! Especially in #TNBC and Luminal B #BreastCancer . Please give us some non-TOPO-1 ADCs!!! #ESMO26

12 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

LBA26按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Short-term preoperative durvalumab for stage I TNBC: First results from the phase II UNLOCK 14 - POP-DURVA trial

https://esmocongress.esmo.org

LBA96按 Proffered paper 2: Breast cancer, early and advanced stage 对上

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts

https://esmocongress.esmo.org

来源：Rebecca Shatsky, MD · x.com